The Movember foundation has awarded a project of Dr. Andreas Doll from the VHIR’s Research Unit in Biomedicine and Translational and Pediatric Oncology. Callded 'Global Action on Urine-Based Detection of Biomarkers for Distinguishing Aggressive from Non-Aggressive Prostate Cancers', it's a joint project of 11 world's leading institutions in the field of prostate cancer research.The other project leaders are: Bharati Bapat, Mount Sinai Hospital, Toronto, Canada, Rob Bristow, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, Canada, Colin Cooper, Schools of Medicine and Biological Sciences, University of East Anglia, Norwich, UK, Hing Leung, The Beatson Institute for Cancer Research. Glasgow, UK, Ian Mills, Centre for Molecular Medicine, Oslo, Norway, David Neal, Cambridge Research Institute, Cambridge, Hardev Pandha, University of Surrey, Guilford, Surrey, Chris Parker, BA, MB, MRCP, MD, FRCR, Royal Marsden Hospital,  UK, Antoinette Perry, Prostate Molecular Oncology, Trinity College Dublin, Ireland, Martin Sanda, Beth Israel Deaconess Medical Center, Boston, MA, USA, and Jack Schalken, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.The translation urology team of the VHIR (Dr. Doll, Dr. Marina Rigau, Dr. Mireia Olivan, Dr. Joan Morote and Dr. Jaume Reventos, the unit's director), together with the teams of Dr. Martin Sanda, Dr. Ian Mills and Dr. Colin Cooper, will create during the next two years a multiplexed RNA biomarker panel for the early diagnosis of prostate cancer in urine to solve the clinical problem that as many as 50-80% of PSA-detected prostate cancers are biologically irrelevant. Even without treatment, they would never have caused any symptoms. Radical treatment of early prostate cancer, with surgery or radiotherapy, should ideally be targeted to men with significant cancers, so that the remainder, with biologically ‘irrelevant’ disease, are spared the side-effects of treatment. Accurate prediction of individual prostate cancer behaviour at the time of diagnosis is not currently possible, and immediate radical treatment for all cases has been a standard approach. Put bluntly, many men are left impotent or incontinent as a result of treatment for a ‘disease’ that would not have troubled them. A large number of prognostic biomarkers have been proposed for prostate cancer. A key question is whether these biomarkers can be applied to PSA-detected, early prostate cancer to distinguish the minority of clinically significant cases from those with biologically irrelevant disease? Validated biomarkers of tumour behaviour could lead to a paradigm-shift in the management of early prostate cancer.The overall goal by the end of the grant period is to better predict aggressive prostate cancer by identifying clinical biomarkers that ultimately enhance treatment decisions. The detection of aggressive PCa at an earlier stage will improve PCa prognosis, which will, in turn, help to reduce health care costs. Finally, the use of urine samples for the final test is attractive because it represents a non-invasive procedure for the early diagnose and is much easier to translate into a widespread clinical practice.  Movember (a portmanteau of the slang word "mo" for moustache and "November") is an annual, month-long event involving the growing of moustaches during the month of November to raise awareness of prostate cancer and other male cancer initiatives. The Movember Foundation runs the Movember charity event, housed at Movember.com. The goal of Movember is to "change the face of men's health.By encouraging men ("Mo Bros") to get involved, Movember aims to increase early cancer detection, diagnosis and effective treatments, and ultimately reduce the number of preventable deaths. Besides getting an annual check-up, the Movember Foundation encourages men to be aware of any family history of cancer, and to adopt a more healthy lifestyle. Since 2004, the Movember Foundation charity has run Movember events to raise awareness and funds for men's health issues, such as prostate cancer and depression, in Australia and New Zealand. In 2007, events were launched in Ireland, Canada, Czech Republic, Denmark, Spain, the United Kingdom, Israel, South Africa, Taiwan and the United States.In 2012 the Global Journal listed Movember as one of the top 100 NGOs (non government organization) in the world.